# Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

> **NCT03382912** · PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 52 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Pegilodecakin
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03382912
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-22
- **Primary completion:** 2019-08-28
- **Final completion:** 2020-03-03
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** The CYPRESS-2 trial was closed early after the planned final analysis because the risk benefit ratio is unfavorable.
- **Last updated:** 2020-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03382912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03382912, "Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03382912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*